May 18, 2020
Triphase Accelerator and Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222 in Patients with Non-Hodgkin's Lymphoma
Apr 21, 2020
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Jan 27, 2020
Global B-cell Non-Hodgkin's Lymphoma Market Review 2017-2019 and Forecast 2020-2028
Jan 14, 2020
John Theurer Cancer Center Investigators Report Transformative Results of CAR T-Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Dec 09, 2019
Researchers at John Theurer Cancer Center, a Member of the Georgetown Lombardi Comprehensive Cancer Center Consortium, Participated in 46 Studies Presented at the 2019 American Society of Hematology's Annual Meeting & Exposition
Dec 08, 2019
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Dec 07, 2019
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Dec 07, 2019
IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
Dec 07, 2019
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen
Nov 14, 2019
FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage
Nov 08, 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Nov 08, 2019
BioInvent to Present BI-1206 Preclinical Data in Mantle Cell lymphoma at ASH 2019
Nov 06, 2019
Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019
Oct 08, 2019
Health Canada approves CALQUENCE® (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma (MCL)
Aug 21, 2019
New Fund to Assist Patients Living with Mantle Cell Lymphoma Opens at the HealthWell Foundation
Aug 11, 2019
A New Model for Lymphoma Drug Discovery
Jul 31, 2019
The mantle cell lymphoma therapeutics market at a CAGR of over 7% during the forecast period
Jul 12, 2019
Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo) Drug Overview & Product Profiles 2016-2026
Jun 14, 2019
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures
Jan 30, 2019
BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma